MDA Space (TSX:MDA): Dilution Is the Point — The Real Question Is Whether the Acquisitions Justify 4.4x Sales

The market has spent the past month asking whether MDA Space's revenue growth can outpace its EPS dilution. That's the wrong variable.

MDA didn't accidentally print shares. The company deliberately raised over $1.1 billion in equity — a $300 million NYSE IPO in March, then an upsized $819 million bought-deal offering in July — to fund two acquisitions totaling approximately $1.27 billion. The dilution isn't a problem to solve; it's the fuel for the strategy. The real question is whether the stock, up 82% year-to-date and trading at 4.38 times trailing sales, has already priced in successful execution or if the math still has runway.

Let's separate the narrative from the arithmetic.

1. Revenue growth is real and accelerating. MDA reported Q2 2026 revenue of $499 million, up 34% year-over-year. Trailing-twelve-month revenue stands at $1.87 billion, up 38%. The company grew fiscal 2025 revenue by 51% on top of an already large base. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a rough cash-earnings proxy) came in at $96.3 million, or 19.3% margin. That's not an aspirational SaaS company burning cash on customer acquisition. This is a defense and space contractor converting a $4.0 billion backlog into revenue with solid operating leverage.

2. The dilution is intentional capital deployment, not passive share creep. Before the IPO, MDA had roughly 129 million shares outstanding. The March IPO added 9.8 million shares. The July offering added another 23 million. The weighted-average diluted share count now sits around 143 million, with a potential over-allotment of up to 3.5 million more. Q2 diluted EPS fell 9.5% year-over-year, but that's an artifact of printing shares, not earnings power deterioration — net income grew 2.6% on GAAP and adjusted net income grew 13%. On a constant-share basis, per-share earnings power was flat to modestly better. The math only works if the acquisitions MDA is funding with this capital actually compound through revenue and margin. If they do, the diluted share base gets a more profitable entity. If they don't, the equity raise looks wasteful.

3. The acquisitions are not scattergun M&A — they're vertical integration. MDA is closing two deals in the same quarter. Blue Canyon Technologies, a smallsat (small satellite) manufacturer being acquired from RTX for $620 million in June, adds hardware manufacturing capability. Collecte Localisation Satellites, a 70% stake acquired for $648 million in July, adds downstream Earth-observation analytics to MDA's upstream satellite data collection. CLS reported €203 million (roughly $232 million) in revenue for 2025, serves over 14,000 customers across defense, maritime, and environmental sectors, and operates 250 proprietary analytics algorithms. Combined with Blue Canyon, MDA's total acquisition spend is $1.27 billion (C$2 billion), fully backed by committed bank financing. CEO Mike Greenley called this a "vertically integrated, AI-driven, advanced data analytics platform for Earth observation." The strategic thesis — moving from satellite hardware and data collection into the higher-margin analytics layer — is coherent. The execution risk is real. Integrating two acquired businesses while maintaining delivery on an existing $4 billion backlog is not easy.

4. The backlog is the structural floor. $4.0 billion in backlog, up $310 million sequentially in Q2 despite the River-class destroyer scope reduction, provides revenue visibility well into 2027 and beyond. Management narrowed full-year 2026 revenue guidance to $1.8–$1.9 billion (roughly 13% growth) and adjusted EBITDA to $330–$370 million (8% growth). The margin guidance of 18–20% is consistent, suggesting management expects the business to grow into operating leverage even during a heavy acquisition integration period. The backlog is contracted revenue, not pipeline hope.

5. The valuation has already run. This is the part that matters most for timing. At $34.59 per share, MDA's market cap is $5.6 billion. The stock trades at 4.38 times trailing sales. Trailing EPS multiple is 72x — elevated, but partly because share-based compensation and integration charges depress GAAP earnings relative to adjusted results. More usefully, EV/EBITDA sits at 24.3x. The stock is up 82% year-to-date versus 13.4% for the broader TSX. Eleven analysts have an average 12-month price target of $67.27 CAD, implying roughly 40% upside from current levels. That target likely reflects acquisition optionality, not base-case standalone growth.

Here's the honest framing. The analyst consensus of "Moderate Buy" is chasing the story rather than pricing it. The 82% YTD run suggests the market has already accepted the vertical-integration thesis and the backlog conversion path. At 4.38x sales, the stock is not at a "major bargain" discount — it's at a premium that assumes the CLS and Blue Canyon acquisitions integrate smoothly and add the revenue the math requires.

But there's still a path for upside, and it doesn't require the stock to be cheap today. CLS alone could add roughly $232 million in revenue and Blue Canyon, while its standalone revenue isn't fully disclosed, adds manufacturing scale that should improve gross margins over time. If the combined entity — organic MDA plus both acquisitions — approaches $3 billion in annual revenue and sustains the 18–20% EBITDA margin guidance, the current 24x EV/EBITDA multiple compresses. That's a growth rate the stock should command at a discount, not a premium. The catalyst isn't dilution resolving itself — it's CLS closing in late 2026 or early 2027, followed by Blue Canyon integration, followed by a combined earnings release that shows the revenue and margin story working as management described it.

The break condition: If Q3 and Q4 2026 results show organic revenue growth holding above the low-end of guidance while backlog stays above $3.7 billion, the market will have confirmation that integration hasn't distracted from execution. That alone could support a re-rate if the stock pulls back from these levels. The Chorus constellation launch, expected in late 2026, is a secondary catalyst — a next-generation SAR satellite that CLS's analytics platform is designed to monetize.

The risk that breaks the thesis: Integration failure. CLS and Blue Canyon are large enough that any disruption to delivery schedules, margin compression from acquisition accounting, or failure to realize cross-selling synergies would undermine the entire rationale for the equity raise. Management has committed to keeping net debt at 1.5–2.5x adjusted EBITDA, and the C$600 million 6.5% senior unsecured notes due 2033 add fixed interest obligations on top of existing debt. If revenue growth decelerates below the guided range while integration costs run hot, the 72x trailing EPS multiple stops looking like a growth premium and starts looking like a trap.

The dilution question is a distraction. The equity raise was a deliberate bet on scale. The stock has already moved on the thesis. The question for new money is whether the acquisition execution — not the share count — can justify what the market is asking.